Price T Rowe Associates Inc Travere Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 281,349 shares of TVTX stock, worth $5.34 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
281,349
Previous 33,441
741.33%
Holding current value
$5.34 Million
Previous $275,000
1331.64%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding TVTX
# of Institutions
194Shares Held
84.6MCall Options Held
776KPut Options Held
900K-
Armistice Capital, LLC New York, NY7.65MShares$145 Million1.78% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$145 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.9MShares$131 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.68MShares$88.9 Million2.23% of portfolio
-
Woodline Partners LP San Francisco, CA4.34MShares$82.3 Million0.55% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.22B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...